Our data suggest that staurosporine derivatives can act as lead compounds for the development of more specific AMPK kinase domain inhibitors with the goal of improved target specificity, anti-cancer efficacy, and reduced treatment complications. The gene discussed is PRKAA1; the disease is cancer.